|
|
||||||||
Clinical Chemistry, Vol 42, 1426-1432, Copyright © 1996 by American Association for Clinical Chemistry
AK Gonschior, U Christians, M Winkler, A Linck, J Baumann and KF Sewing
Institut fur Allgemeine Pharmakologie, Hannover, Germany.
The metabolite patterns of tacrolimus in blood were evaluated in 41 kidney and liver graft recipients. Trough concentrations of tacrolimus and its metabolites were measured by HPLC-mass spectrometry and microparticle enzyme immunoassay in parallel. A statistically significant correlation between results of both assays was observed for kidney and liver transplant patients (r = 0.77, P <0.001 and r = 0.71, P <0.001, respectively). The main metabolites in blood were demethyl, demethylhydroxy, didemethyl, didemethylhydroxy, and hydroxy tacrolimus. These metabolites added up to 42% (range 0-145%) of the tacrolimus concentration in liver transplant patients and to 44.8% (range 16-152%) in kidney transplant patients. During episodes of impaired liver function, concentrations of tacrolimus and its metabolites were increased compared with normal liver function, indicating accumulation of metabolites, in particular second-generation metabolites such as didemethyl and didemethylhydroxy tacrolimus. Stepwise regression analysis including tacrolimus, its metabolites, and liver function parameters suggested a model including serum activities of gamma- glutamyltransferase, alkaline phosphatase, and alanine aminotransferase as predictors for increased concentrations of demethyl tacrolimus, didemethyl tacrolimus, and the parent drug.
The following articles in journals at HighWire Press have cited this article:
![]() |
N. W. Brown, C. E. Gonde, J. E. Adams, and J. M. Tredger Low Hematocrit and Serum Albumin Concentrations Underlie the Overestimation of Tacrolimus Concentrations by Microparticle Enzyme Immunoassay versus Liquid Chromatography-Tandem Mass Spectrometry Clin. Chem., March 1, 2005; 51(3): 586 - 592. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. MacFarlane, D. G. Scheller, D. L. Ersfeld, L. M. Shaw, R. Venkatarmanan, L. Sarkozi, R. Mullins, and B. R. Fox Analytical Validation of the PRO-Trac II ELISA for the Determination of Tacrolimus (FK506) in Whole Blood Clin. Chem., September 1, 1999; 45(9): 1449 - 1458. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Steimer Performance and Specificity of Monoclonal Immunoassays for Cyclosporine Monitoring: How Specific Is Specific? Clin. Chem., March 1, 1999; 45(3): 371 - 381. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. Armstrong, E. Schuetz, Q. Zhang, S. Groothuisen, C. Scholz, M. Shipkova, H. Aboleneen, and M. Oellerich Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography–tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II) Clin. Chem., December 1, 1998; 44(12): 2516 - 2523. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |